Lairson DR, Parikh RC, Cormier JN, Du XL. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Value Health. 2014 Feb;17(1):34-42.
Ling CS, Weisgerber-Kriegl U, Njue AI, Heyes A, Kaye J. The effect of positive margins on outcomes in breast cancer. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A394.
Ara R, Basarir H, Keetharuth A, Weatherly H, Barbieri M, Sculpher MJ. Economic evidence of surgical procedures in cancer: a systematic literature review. Poster presented at the 2013 ISPOR 16th Annual European Congress; October 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A411. doi: 10.1017/S0266462314000531
Mladsi DM, Ronquest NA, Tannus G, Fonseca M, Saag K. Estimated cost effectiveness of lower-dose submicron diclofenac compared with traditional diclofenac in Brazil. Poster presented at the 2013 ISPOR 4th Latin America Conference; September 2013. Buenos Aires, Argentina. [abstract] Value Health. 2013 Sep; 16(7):PA717-8. doi: 10.1016/j.jval.2013.08.2226
Mitra D, Whiteley J, Iyer S, Candrilli S, Kaye JA. Treatment and response patterns in chronic myeloid leukemia: evidence from a retrospective study in Canada, Australia, and South Korea. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A413. doi: 10.1016/j.jval.2012.08.1217
Meyers J, Yu Y, Davis KL. Patient survival, health care utilization, and costs in Medicare patients with acute myeloid leukemia compared to matched controls. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 1, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A214.
Mitra D, Trask P, Iyer S, Candrilli S, Kaye J. A multi-country retrospective study of patient characteristics and treatment patterns in chronic myeloid leukemia. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 10, 2011. [abstract] Value Health. 2011 Nov; 14(7):A468.
Dalal AA, Nelson L, Gilligan TM, McLeod LD, Lewis SE, DeMuro C. Measurement comparability between paper and alternate versions: recommended assessment steps using the lung function questionnaire as an example. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 25, 2011. [abstract] Value Health. 2011 May; 14(3):A145.
Mitra D, Candrilli SD. Acute lymphocytic leukemia–related inpatient care among pediatric patients in the United States. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 25, 2011. [abstract] Value Health. 2011 May; 14(3):A163.
Gilligan TM, Nelson L, Dalal AA, McLeod LD. Visually evaluating the measurement comparability between paper-based and alternate versions of administration of the lung function questionnaire. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 25, 2011. [abstract] Value Health. 2011 May; 14(3):A153.
Meyers J, Mitra D, Doan J, Leeflang C. The role of patient selection criteria in identifying ovarian cancer patients in a retrospective database analysis. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. [abstract] Value Health. 2010 Nov; 13(7):A281.
Colosia AD, Khan SB, Peltz G, Pohl G, Liu E, Kaye JA. Electronic medical records: quality cancer care and cost-effectiveness. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A52.
Earnshaw S, McDade CL, Black L, Kattan M. Cost-effectiveness of chemoprevention with dutasteride based on results from the REDUCE clinical trial. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A371.
Wolowacz S, Roskell N, Plumb J, Clemens A, Robinson P, Dolan G, Brenkel I. Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty that have moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. [abstract] Value Health. 2009 May; 12(3):A151.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150 MG for the prevention of venous thromboembolism in patients aged over 75 years undergoing total hip or knee arthroplasty. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 14, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.
Hauber AB, Lam A, Fleishmann J, Wilson MR. European economic evaluation of OROS hydromorphone in the management of severe chronic cancer and non-cancer pain. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A640.
Odom D, Devercelli G, Bennett L, Peeters M, Wolf M, Amado R. Health-related quality of life (HRQOL) and colorectal cancer (CRC) symptoms in metastatic CRC: panitumumab plus best supportive care (BSC) versus bsc alone by kras tumor status. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 12, 2008. [abstract] Value Health. 2008 Nov; 11(6):487.
Mitra D, Davis KL, Kotapati S, Iloeje U. Real-world treatment patterns in high-risk and metastatic melanoma: evidence from the SEER-medicare linked database. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A83.
Davis KL, Mitra D, Kotapati S. Direct economic burden of high-risk and metastatic melanoma: evidence from the SEER-medicare linked database. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A69-70.
Kotapati S, Mitra D, Davis KL, Iloeje U. Predictors of treatment choice in high-risk and metastatic melanoma: evidence from linked electronic medical records and administrative claims data. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A82-3.
Brennan VK, Wolowacz SE. A systematic review of breast cancer utility weights. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A77.
Wolowacz SE, Roskell NS, Christie A, Kerr G, Cameron D. Per-patient cost of hospital care for advanced breast cancer in the UK based on a large patient-level resource utilisation dataset. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6):A42.
Abetz L, Coombs JH, Keininger DL, Earle CC, Wade C, Bury-Maynard D, Copley-Merriman K, Hsu MA. Development of the cancer chemotherapy satisfaction questionnaire (CCSQ): item generation and content validity testing. Value Health. 2005 Nov;8(Suppl 1):S41-53.
Yost KJ, Sorenson MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health. 2005 Mar;8(2):117-27.
McBurney C, Coombs J, Hsu M, Abetz L, Keininger D, Copley-Merriman K. An appraisal of treatment satisfaction and patient preference assessments in patients diagnosed with cancer. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; 2003. [abstract] Value Health. 5(3):201.
Sorensen SV, Chambers M, Heyes AE. An economic model for the pharmacological management of advanced non-small cell lung cancer in the US. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; 2001. Cannes, France. [abstract] Value Health. 2001 Sep; 4(6):403.